| Perry E Bassett, MD | |
|
4201 N Soncy Rd, Amarillo, TX 79124-5724 | |
| (806) 231-4946 | |
| (806) 677-0018 |
| Full Name | Perry E Bassett |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 29 Years |
| Location | 4201 N Soncy Rd, Amarillo, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245233857 | NPI | - | NPPES |
| 1245233857 | Medicaid | IA | |
| 200575060A | Medicaid | KS | |
| 1245233857 | Medicaid | MO | |
| 200069550A | Medicaid | OK | |
| 7100144460 | Medicaid | KY | |
| 1245233857 | Medicaid | VA | |
| 4315971 | Medicaid | OH | |
| 133605913 | Medicaid | TX | |
| 200575060E | Medicaid | KS | |
| 3810016569 | Medicaid | WV | |
| 10025874900 | Medicaid | NE | |
| 133605909 | Medicaid | TX | |
| 1521898 | Medicaid | TN | |
| 4315972 | Medicaid | OH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southwest Medical Center | Liberal, KS | Hospital |
| Rehoboth Mckinley Christian Health Care Services | Gallup, NM | Hospital |
| Bob Wilson Memorial Grant County Hospital | Ulysses, KS | Hospital |
| Western Plains Medical Complex | Dodge city, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Medical Group Pllc | 0446296818 | 158 |
| Ess Of Port Lavaca Llc | 2769766005 | 22 |
| Rural Kansas Emergency Physicians Llc | 8921269481 | 6 |
| Emergency Staffing Solutions Inc | 9830001650 | 28 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Brazos Valley Emergency Physicians Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982642955 PECOS PAC ID: 0749276772 Enrollment ID: O20040521001234 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Acs Primary Care Physicians Southwest Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538101019 PECOS PAC ID: 1850204363 Enrollment ID: O20041206000027 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Texas Emergency Staffing Solutions Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811942949 PECOS PAC ID: 0345297610 Enrollment ID: O20050407001290 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Brewster Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538218771 PECOS PAC ID: 1254430481 Enrollment ID: O20070628000245 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Texas Ess Hospitalist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235472556 PECOS PAC ID: 8921248162 Enrollment ID: O20140115001155 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Longhorn Emergency Medical Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649669672 PECOS PAC ID: 4486971041 Enrollment ID: O20150320000152 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Emergency Staffing Solutions Of West Texas Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033593504 PECOS PAC ID: 7113237868 Enrollment ID: O20151109000839 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Ess Of Nacogdoches Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780139956 PECOS PAC ID: 3375821630 Enrollment ID: O20161021000335 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Ess Of Port Lavaca Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922546936 PECOS PAC ID: 2769766005 Enrollment ID: O20170303001868 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Town Square Emergency Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457890402 PECOS PAC ID: 9931485604 Enrollment ID: O20170412000070 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Apptexased Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265945539 PECOS PAC ID: 7911264296 Enrollment ID: O20171121001615 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Texas Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699288811 PECOS PAC ID: 0345508768 Enrollment ID: O20171212003035 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Ess Of Fairfield Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588132856 PECOS PAC ID: 9234475526 Enrollment ID: O20190108000545 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Entity Name | Hcc Of Fairfield Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487122750 PECOS PAC ID: 3072859099 Enrollment ID: O20190114000163 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Perry E Bassett, MD 4201 N Soncy Rd, Amarillo, TX 79124-5724 Ph: (806) 231-4946 | Perry E Bassett, MD 4201 N Soncy Rd, Amarillo, TX 79124-5724 Ph: (806) 231-4946 |
News Archive
Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University's College of Education.
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of the UltraPulse DUO at the 119th Annual American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting, taking place September 27 - 30, 2015 in Dallas, Texas.
Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.
Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.
› Verified 3 days ago
Joseph D Hollingsworth, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Wallace Blvd, Baptist Saint Anthony's Hospital, Amarillo, TX 79106 Phone: 806-212-2000 | |
Mike Preston Berry Jr., M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Wallace Blvd, Amarillo, TX 79106 Phone: 806-212-2000 Fax: 806-212-2735 | |
Christopher M Bradburry, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1501 S Coulter St, Amarillo, TX 79106 Phone: 806-354-1000 | |
Matthew W Turney, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2101 S Coulter St, Amarillo, TX 79106 Phone: 806-350-7744 Fax: 806-350-7776 | |
Alicia Irene Balderas, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1616 S Kentucky St Ste B100, Amarillo, TX 79102 Phone: 806-355-8900 | |
Darrell I Morgan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3440 Bell St, Suite 320, #186, Amarillo, TX 79109 Phone: 806-322-3230 | |
Robert N. Reddix Jr., MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3501 S Soncy Rd Ste 104, Amarillo, TX 79119 Phone: 806-398-3627 Fax: 806-351-7801 |